MedTrace Logo

XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization

NCT03745053 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-02-07

No results posted yet for this study

Summary

The objective of the study is to assess angiographic and clinical performance of Xlimus Drug Eluting Stent (DES) compared to Synergy Bioabsorbable Polymer Everolimus Eluting Stent in patients treated with percutaneous coronary angioplasty

Conditions

Interventions

DEVICE

Xlimus DES Implantation during coronary angioplasty

Xlimus DES Implantation during coronary angioplasty

DEVICE

Synergy DES Implantation during coronary angioplasty

Synergy DES Implantation during coronary angioplasty

Sponsors & Collaborators

  • Mediolanum Cardio Research

    collaborator OTHER

  • Cardionovum GmbH

    lead INDUSTRY

Principal Investigators

  • Luca Testa, MD · IRCCS Policlinico S. Donato

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-05
Primary Completion
2023-09-02
Completion
2023-09-02

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03745053 on ClinicalTrials.gov